1. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
- Author
-
Richardson, Leland G., Nieman, Linda T., Stemmer-Rachamimov, Anat O., Zheng, Xijin S., Stafford, Khalifa, Nagashima, Hiroaki, Miller, Julie J., Kiyokawa, Juri, Ting, David T., Wakimoto, Hiroaki, Cahill, Daniel P., Choi, Bryan D., and Curry, William T.
- Subjects
- *
SUPPRESSOR cells , *ISOCITRATE dehydrogenase , *GLIOMAS , *T cells , *MULTISPECTRAL imaging - Abstract
The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-based therapies, a better understanding on their association with IDH mutational status remains of critical clinical importance. Using multispectral imaging analysis, we compared the incidence of Tregs in IDH-mutant and IDH wild-type glioma from patient tumor samples of LGG. An orthotopic IDH-mutant murine model was generated to evaluate the role of mutant IDH on Treg infiltration by immunohistochemistry. When compared to IDH wild-type controls, Tregs are disproportionally underrepresented in mutant disease, even when taken as a proportion of all infiltrating T cells. Our findings suggest that therapeutic agents targeting Tregs may be more appropriate in modulating the immune response to wild-type disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF